Hematology-Oncology
Ahn, Jin Seok
95 AppointmentProfessor, Department of Hematology & Oncology, Samsung Medical Center
Speciality Interests
Schedule
05 | THU 01 |
FRI 02 |
MON 05 |
TUE 06 |
WEN 07 |
---|---|---|---|---|---|
AM | |||||
PM |
Medical School
2000~2003 Ph.D. in Medicine Catholic University, Korea 1994~1996 Master of Science Seoul National University, Korea 1982~1988 College of Medicine, Seoul National University, Korea
Specialty Training
Fellowship | 1996~1997 Division of Hematology & Medical Oncology, Seoul National University Hospital, Korea | |
---|---|---|
Residency | 1992~1996 Department of Internal Medicine, Seul National University Hospital, Korea | |
Internship | 1988~1989 Seoul National University Hospital, Korea |
Other Education
2019~2021 Chair Division of Hematology-Oncology, Samsung Medical Center
2017~2019 Director Supportive Care Center, Samsung Medical Center
2015~2017 Director Breast Cancer Center, Samsung Medical Center
2011~Present Professor Department of Medicine, Sungkyunkwan University School of Medicine
2005~2011 Associate Professor Department of Medicine, Sungkyunkwan University School of Medicine
2003~2005 Associate Professor Department of Medicine, Hallym University College of Medine
1999~2003 Assistant Professor Department of Medicine, Hallym University College of Medine
1997~1999 Clinical Instructor Department of Medicine, Hallym University College of Medine
Participation in Academic Societies
and Research
2021~Present Director Lung Cancer Committee, KCSG
2016~Present Member Multinational Association of Supportive Care in Cancer (MASCC)
2015~Present Member European Society of Medical Oncology (ESMO)
2010~Present Member Korean Society for Hospice and Palliative Care
2008~Present Member Americal Society of Clinical Oncology (ASCO)
2007~Present Member Korean Association for Lung Cancer (KALC)
2007~Present Member International Association for the Study of Lung Cancer (IASLC)
2006~Present Member Korean Society of Medical Oncology (KSMO)
2000~Present Member Korean Cancer Study Group (KCSG)
1995~Present Member Korean Cancer Association (KCA)
Thesis
FRONT ONCOL 2021 10.3389/fonc.2021.596364
Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry
CANCER 2021 10.1002/cncr.33571
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program
FRONT ONCOL 2021 10.3389/fonc.2021.653243
The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
J KOREAN NEUROSURG SOC 2021 10.3340/jkns.2020.0135
Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery
DIAGNOSTICS 2021 10.3390/diagnostics11020370
Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea
EUR J IMMUNOL 2021 10.1002/eji.202048966
Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer
TRANSL LUNG CANCER R 2021 10.21037/tlcr-20-1128
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
CLIN APPL THROMB-HEM 2021 10.1177/1076029620979575
Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study
IMMUNE NETW 2020 10.4110/in.2020.20.e48
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
SCI REP-UK 2020 10.1038/s41598-020-76130-1
Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
CANCER RES TREAT 2020 10.4143/crt.2020.278
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
BIOLOGY-BASEL 2020 10.3390/biology9100326
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations?
TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
ANN ONCOL 2020 10.1016/j.annonc.2020.06.017
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
J THORAC DIS 2020 10.21037/jtd-20-1671
Characteristics of female lung cancer in Korea analysis of Korean National Lung Cancer Registry
MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer
SCI REP-UK 2020 10.1038/s41598-020-70168-x
Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations
EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors
LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
BREAST CANCER RES TR 2020 10.1007/s10549-020-05874-1
Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer
ANN ONCOL 2020 10.1016/j.annonc.2020.04.478
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033
Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)
ANN ONCOL 2020 10.1016/j.annonc.2020.04.004
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients
EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932
Evaluating entrectinib as a treatment option for non-small cell lung cancer
J THORAC DIS 2020 10.21037/jtd.2019.08.29
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
CANCER RES TREAT 2020 10.4143/crt.2019.713
Ramosetron versus Palonosetron in Combination with Aprepitant and Dexamethasone for the Control of Highly-Emetogenic Chemotherapy-Induced Nausea and Vomiting
CANCER 2020 10.1002/cncr.32809
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer
EUR J CANCER 2020 10.1016/j.ejca.2020.03.029
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
NAT COMMUN 2020 10.1038/s41467-020-16164-1
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
IN VIVO 2020 10.21873/invivo.11920
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping
CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests
CANCERS 2020 10.3390/cancers12051306
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience
J PAIN SYMPTOM MANAG 2020
Reliability and Validity of the Korean Language Version of the US National Cancer Institute?s Patient -Reported Outcomes Common Terminology Criteria for Adverse Events
SUPPORT CARE CANCER 2020 10.1007/s00520-019-04982-z
Impact of a topical lotion, CG428, on permanent chemotherapy-induced alopecia in breast cancer survivors: a pilot randomized double-blind controlled clinical trial (VOLUME RCT)
INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Cancer Med 2020 10.1002/cam4.2868
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence
J CLIN ONCOL 2020 10.1200/JCO.19.00457
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
J CLIN ONCOL 2020 10.1200/JCO.19.00931
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
CANCER RES TREAT 2020 10.4143/crt.2019.186
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
LUNG CANCER 2020 10.1016/j.lungcan.2019.10.015
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer
BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
Oncoimmunology 2020 10.1080/2162402X.2020.1722023
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
INT J CANCER 2019 10.1002/ijc.32235
Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease
EUR J CANCER 2019 10.1016/j.ejca.2019.08.001
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
CANCER RES TREAT 2019 10.4143/crt.2018.704
Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014
NAT COMMUN 2019 10.1038/s41467-019-12159-9
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
SCI REP-UK 2019 10.1038/s41598-019-48674-4
Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer
JAMA Oncol 2019 10.1001/jamaoncol.2019.0339
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer Final Analysis of the HannaH Phase 3 Randomized Clinical Trial
J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor
J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
CANCER RES TREAT 2019 10.4143/crt.2018.262
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer
CANCER RES TREAT 2019 10.4143/crt.2018.342
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
CANCER RES TREAT 2019 10.4143/crt.2018.324
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
CANCER RES TREAT 2019 10.4143/crt.2018.117
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
CANCER RES TREAT 2019 10.4143/crt.2018.125
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-1449
The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
CANCER RES TREAT 2019 10.4143/crt.2018.151
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
CANCER RES TREAT 2019 10.4143/crt.2018.366
Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
ONCOLOGIST 2019 10.1634/theoncologist.2018-0184
Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study
ONCOL LETT 2019 10.3892/ol.2018.9754
Clinical features and prognosis of breast cancer with gastric metastasis
MEDICINE 2019 10.1097/MD.0000000000014278
Sedation for terminally ill cancer patients A multicenter retrospective cohort study in South Korea
J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
CLIN NUCL MED 2019 10.1097/RLU.0000000000002394
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer FDG Uptake and Risk Stratification
EUR J NUCL MED MOL I 2019 10.1007/s00259-018-4138-5
Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer
HERED CANCER CLIN PR 2019 10.1186/s13053-018-0103-3
The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans
CANCER RES TREAT 2019 10.4143/crt.2018.138
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
BMC CANCER 2019 10.1186/s12885-018-5258-9
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
BREAST CANCER RES TR 2019 10.1007/s10549-018-4981-x
A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients
J BREAST CANC 2018 10.4048/jbc.2018.21.e48
PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
INT J CANCER 2018 10.1002/ijc.31651
A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial
EUR J CANCER 2018 10.1016/j.ejca.2018.08.004
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010
Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment
BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z
Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
LUNG CANCER 2018 10.1016/j.lungcan.2018.06.009
Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma
J THORAC ONCOL 2018 10.1016/j.jtho.2018.04.038
Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication
J BREAST CANC 2018 10.4048/jbc.2018.21.2.206
Which Patients with Left Breast Cancer Should be Candidates for Heart-Sparing Radiotherapy?
Clin Pharmacol Drug Dev 2018 10.1002/cpdd.427
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
ASIA-PAC J CLIN ONCO 2018 10.1111/ajco.12696
Inadequate treatment practices for pain relief and adverse eventmanagement in cancer patients across 10 countries/regions in Asia: a call for greater efforts to improve standards for patient care
AM J HEMATOL 2018 10.1002/ajh.25043
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
LUNG CANCER 2018 10.1016/j.lungcan.2018.02.020
Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea
Oncoimmunology 2018 10.1080/2162402X.2018.1466768
Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
PLoS One 2018 10.1371/journal.pone.0194730
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
NAT COMMUN 2018 10.1038/s41467-018-04129-4
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
BRIT J CANCER 2018 10.1038/bjc.2017.465
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)
LUNG CANCER 2018 10.1016/j.lungcan.2018.01.004
Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy
J BREAST CANC 2018 10.4048/jbc.2018.21.1.91
Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy
J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.014
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma
J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.007
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer
J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.011
Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
BMC CANCER 2018 10.1186/s12885-017-3965-2
A train the trainer program for healthcare professionals tasked with providing psychosocial support to breast cancer survivors
LUNG CANCER 2018 10.1016/j.lungcan.2017.11.020
Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer
J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer
Lancet Respir Med 2017 10.1016/S2213-2600(17)30378-8
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
NAT COMMUN 2017 10.1038/s41467-017-01470-y
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
CANCER RES TREAT 2017 10.4143/crt.2016.442
Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience
EXPERT REV MOL DIAGN 2017 10.1080/14737159.2017.1372196
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer
J THORAC ONCOL 2017 10.1016/j.jtho.2017.06.070
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer
ONCOTARGET 2017
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
BREAST CANCER RES TR 2017 10.1007/s10549-017-4304-7
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial
CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3396-4
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors
Chin J Cancer 2017 10.1186/s40880-017-0241-4
Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12652
Clinical outcomes according to molecular subtypes in stage II-III breast cancer patients treated with neoadjuvant chemotherapy followed by surgery and radiotherapy
NEW ENGL J MED 2017 10.1056/NEJMoa1704795
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
J Pain Res 2017 10.2147/JPR.S140320
Transdermal buprenorphine and fentanyl patches in cancer pain: a network systematic review
BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy
ONCOTARGET 2017 10.18632/oncotarget.17653
Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response
Eur J Cancer. 2017 May;76:205-215. doi: 10.1016/j.ejca.2017.02.011. Epub 2017 Mar 27.
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial
Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881.
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8.
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283.
Osimertinib for the treatment of non-small cell lung cancer
Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414.
The effect of androgen receptor expression on clinical characterization of metastatic breast cancer
Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7.
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652
Pembrolizumab for the treatment of non-small cell lung cancer
BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
PLoS One. 2016 Feb 22;11(2):e0149432. doi: 10.1371/journal.pone.0149432. eCollection 2016.
The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130.
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision
J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14.
Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?
Breast Cancer Res Treat. 2016 Dec;160(3):475-489. doi: 10.1007/s10549-016-4008-4. Epub 2016 Oct 11.
Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems
J Thorac Dis. 2016 Nov;8(11):3175-3186. doi: 10.21037/jtd.2016.11.25.
The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations
World Neurosurg. 2016 Nov;95:399-405. doi: 10.1016/j.wneu.2016.08.046. Epub 2016 Aug 24.
Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer
Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17.
Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study
Lung Cancer. 2016 Oct;100:24-29. doi: 10.1016/j.lungcan.2016.07.025. Epub 2016 Jul 26.
Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor
Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18.
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11.
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035.
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency
PLoS One. 2016 Sep 20;11(9):e0163254. doi: 10.1371/journal.pone.0163254. eCollection 2016.
Clinicopathological Features and Prognostic Factors Affecting Survival Outcomes in Isolated Locoregional Recurrence of Breast Cancer: Single-Institutional Series
SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804
The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5.
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells
Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
Eur J Cancer. 2016 Jul;62:62-75. doi: 10.1016/j.ejca.2016.03.087. Epub 2016 May 20.
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up
J Breast Cancer. 2016 Jun;19(2):169-75. doi: 10.4048/jbc.2016.19.2.169. Epub 2016 Jun 24.
Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes
Clin Breast Cancer. 2016 Jun;16(3):e15-21. doi: 10.1016/j.clbc.2015.11.008. Epub 2015 Dec 11.
Limited Supraclavicular Radiation Field in Breast Cancer With >= 10 Positive Axillary Lymph Nodes
Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.
Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26.
Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria
Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623.
Gene Expression Profiling of Breast Cancer Brain Metastasis
Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14.
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443. Epub 2015 Nov 23.
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study
JOURNAL OF CLINICAL ONCOLOGY, MAR 1 2016, 34(7):768-+, DOI: 10.1200/JCO.2015.65.1042
Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer Reply
Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874.
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
Oncotarget. 2015 Sep 15;6(27):24499-510.
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial
J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04
J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25.
BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
Oncologist. 2015 Dec;20(12):1440-7. doi: 10.1634/theoncologist.2015-0128. Epub 2015 Oct 28.
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21
Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192.
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer
Clin Breast Cancer. 2015 Dec;15(6):512-8. doi: 10.1016/j.clbc.2015.06.004. Epub 2015 Jun 18.
Clinical Outcomes and Prognostic Factors of Pathologic N3 Breast Cancer Treated With Modern Standard Treatments
J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692.
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors
Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4.
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
J Neurooncol. 2015 Nov;125(2):331-8. doi: 10.1007/s11060-015-1915-x. Epub 2015 Sep 15.
Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer
Lancet Oncol. 2015 Nov;16(15):1556-68. doi: 10.1016/S1470-2045(15)00332-0. Epub 2015 Oct 22.
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Cancer Res Treat. 2015 Oct;47(4):765-73. doi: 10.4143/crt.2014.168. Epub 2015 Jan 13.
Impact on Survival of Regular Postoperative Surveillance for Patients with Early Breast Cancer
ONCOTARGET, OCT 13 2015, 6(31), 30929-30938, 10.18632/oncotarget.5131
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12.
Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188.
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis
Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184.
Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
Ann Oncol. 2015 Jan;26(1):161-6. doi: 10.1093/annonc/mdu504. Epub 2014 Oct 29.
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing
Cancer Med. 2015 Aug;4(8):1196-204. doi: 10.1002/cam4.471. Epub 2015 Apr 27.
Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries
Breast Cancer Res Treat. 2015 Aug;152(3):675-82. doi: 10.1007/s10549-015-3502-4. Epub 2015 Jul 22.
Quantitative changes in skin composition parameters due to chemotherapy in breast cancer patients: a cohort study
Breast Cancer Res Treat. 2015 Jul;152(1):77-85. doi: 10.1007/s10549-015-3450-z. Epub 2015 Jun 2.
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)
Support Care Cancer. 2015 Jun;23(6):1769-77. doi: 10.1007/s00520-014-2507-6. Epub 2014 Dec 3.
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients
Cancer Chemother Pharmacol. 2015 Jun;75(6):1229-36. doi: 10.1007/s00280-015-2740-9. Epub 2015 Apr 23.
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
Breast. 2015 Jun;24(3):213-7. doi: 10.1016/j.breast.2015.01.012. Epub 2015 Feb 24.
Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea
Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23.
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer
Int J Cancer. 2015 Apr 15;136(8):1976-84. doi: 10.1002/ijc.29233. Epub 2014 Dec 24.
A seven-gene signature can predict distant recurrence in patients with triple- negative breast cancers who receive adjuvant chemotherapy following surgery
J Breast Cancer. 2015 Mar;18(1):50-6. doi: 10.4048/jbc.2015.18.1.50. Epub 2015 Mar 27.
Proportion and Clinical Outcomes of Postoperative Radiotherapy Omission after Breast-Conserving Surgery in Women with Breast Cancer
Pharmacogenomics. 2015;16(4):383-91. doi: 10.2217/pgs.15.14.
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients
Tumour Biol. 2015 Feb;36(2):1073-9. doi: 10.1007/s13277-014-2730-2. Epub 2014 Oct 19.
Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology
Cancer Chemother Pharmacol. 2014 Sep;74(3):521-9. doi: 10.1007/s00280-014-2542-5. Epub 2014 Jul 22.
Clinicopathological features of early failure of neoadjuvant chemotherapy in locally advanced breast cancer
Oncology. 2014;86(5-6):279-88. doi: 10.1159/000362281. Epub 2014 Jun 4.
Validation and Comparison of CS-IHC4 Scores with a Nomogram to Predict Recurrence in Hormone Receptor-Positive Breast Cancers
Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27.
Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13.
Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy
Cancer Chemother Pharmacol. 2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25.
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs
Cancer Res Treat. 2014 Apr;46(2):200-3. doi: 10.4143/crt.2014.46.2.200. Epub 2014 Apr 22.
Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma
J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21
Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28.
A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin
Eur J Cancer. 2014 Mar;50(4):698-705. doi: 10.1016/j.ejca.2013.11.028. Epub 2013 Dec 18.
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy
Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20.
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma
Br J Cancer. 2014 Jan 21;110(2):384-91. doi: 10.1038/bjc.2013.757. Epub 2013 Dec 17.
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9.
Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3.
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease
Cancer Res Treat. 2014 Apr;46(2):131-40. doi: 10.4143/crt.2014.46.2.131. Epub 2014 Apr 22.
A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians
Support Care Cancer. 2014 Mar;22(3):741-50. doi: 10.1007/s00520-013-2030-1. Epub 2013 Nov 8.
A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics
Lung Cancer. 2013 Dec;82(3):455-60. doi: 10.1016/j.lungcan.2013.08.027. Epub 2013 Sep 8.
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy
Lung Cancer. 2013 Aug;81(2):231-5. doi: 10.1016/j.lungcan.2013.04.011. Epub 2013 May 14.
The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer
Ann Oncol. 2013 Jun;24(6):1485-90. doi: 10.1093/annonc/mds658. Epub 2013 Feb 4.
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905)
J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12.
Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer
J Breast Cancer. 2012 Jun;15(2):239-43. doi: 10.4048/jbc.2012.15.2.239. Epub 2012 Jun 28.
Survey of the Application of the Korean Clinical Practice Recommendations on Breast Cancer Treatment: The Utility of the Korean Breast Cancer Society Guidelines
J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Breast Cancer Res Treat. 2012 Apr;132(2):589-600. doi: 10.1007/s10549-011-1852-0. Epub 2011 Nov 18.
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01
Support Care Cancer. 2010 Feb;19(2):297-301. doi: 10.1007/s00520-010-0825-x. Epub 2010 Mar 7.
The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study
Lung Cancer. 2011 Jan;71(1):89-93. doi: 10.1016/j.lungcan.2010.04.003. Epub 2010 Jul 3.
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases
Breast Cancer Res Treat. 2011 Jan;125(1):99-106. doi: 10.1007/s10549-010-1201-8. Epub 2010 Oct 5.
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)
BMC Cancer. 2010 Oct 5;10:527. doi: 10.1186/1471-2407-10-527.
Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype
Lung Cancer. 2010 Sep;69(3):323-9. doi: 10.1016/j.lungcan.2009.12.002. Epub 2010 Jan 12.
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer
Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24.
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib
Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719.
Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer
Oncology.?2008;74 Suppl 1:4-6. doi: 10.1159/000143211. Epub 2008 Aug 28.
Progress of cancer pain management in Korea